This inventor holds 1 USPTO granted patent. Top assignee: Regents of the University of Minnesota. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Innovations by John A Conrad in Brain Cancer Treatment
Introduction
John A Conrad is an accomplished inventor based in Lino Lakes, MN (US). He has made significant contributions to the field of medical science, particularly in the treatment of primary brain cancer. His innovative work has led to the development of a unique patent that addresses a critical health issue.
Latest Patents
John A Conrad holds a patent for "Antisense oligonucleotides and methods for treating central nervous." This invention provides compositions and methods for treating primary brain cancer. The compositions include at least one antisense oligonucleotide that inhibits the proliferation of primary brain cancer cells. The antisense oligonucleotides are designed to be complementary to and hybridize with mRNA encoding c-myb. The method involves treating patients with primary brain cancer using a pharmaceutical composition that includes at least one antisense oligonucleotide in an effective amount to inhibit primary brain cell proliferation. Additionally, the invention provides probes and primers useful for identifying primary brain cells with amplified and/or rearranged genes encoding c-myb.
Career Highlights
John A Conrad is associated with the Regents of the University of Minnesota, where he has been able to leverage his expertise in research and innovation. His work has not only advanced scientific understanding but has also opened new avenues for therapeutic interventions in oncology.
Collaborations
Some of his notable coworkers include Walter A Hall and Lan Chiang. Their collaborative efforts have contributed to the success of the projects they have undertaken together.
Conclusion
John A Conrad's innovative contributions to the treatment of primary brain cancer through his patented methods highlight the importance of research and development in medical science. His work continues to inspire advancements in cancer treatment and offers hope for patients facing this challenging disease.